COVID‐19: vaccination problems

Summary This minireview addresses problems of financing the vaccine development, regulatory questions, the ethics and efficacy of vaccine prioritization strategies and the coverage of variant viruses by current vaccines. Serious adverse effects observed with adenovirus vectored vaccines and mRNA vac...

Full description

Saved in:
Bibliographic Details
Published inEnvironmental microbiology Vol. 23; no. 6; pp. 2878 - 2890
Main Author Brüssow, Harald
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.06.2021
Wiley Subscription Services, Inc
Subjects
Clinical trials
COVID-19
COVID-19 infection
COVID-19 vaccines
Disease control
Ethics
Financing
Immunization
Lilliput
mRNA
Placebos
prioritization
seroprevalence
Vaccination
Vaccine development
Vaccines
Viruses
Online AccessGet full text

Cover

More Information
Summary:Summary This minireview addresses problems of financing the vaccine development, regulatory questions, the ethics and efficacy of vaccine prioritization strategies and the coverage of variant viruses by current vaccines. Serious adverse effects observed with adenovirus vectored vaccines and mRNA vaccines in mass vaccination campaigns are reported. The ethical problems of continuing with placebo controlled vaccine trials and alternative clinical trial protocols are discussed as well as concrete vaccination issues such as the splitting of doses, the delaying of the second dose, the immunization with two different vaccine types and the need of vaccinating seropositive subjects. Strategies to increase vaccine acceptance in the population are shortly mentioned.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1462-2912
1462-2920
1462-2920
DOI:10.1111/1462-2920.15549